Effect of Immune Plasma Therapy on Mortality and Morbidity in Patients with Covid-19: A Retrospective Study

Main Article Content

Hayriye Bektaş Aksoy
İskender Aksoy
Selda Günaydın
Abdülbaki Elmas
Ahmet Cumhur Dülger


Objective: Immune plasma therapy, a method employed for passive immunization, has been utilized as a treatment modality based on historical precedents during the Covid-19 pandemic, a global crisis resulting in the unfortunate demise of countless individuals. The objective of this study is to investigate the impact of immune plasma therapy on laboratory parameters and the overall survival rate in patients with Covid-19 pneumonia.

Material and Methods: Our study was designed as a retrospective analysis, conducted at a tertiary healthcare institution from April 1, 2020, to December 31, 2020. The study population comprised individuals aged 18 and above, presenting with pulmonary involvement, and diagnosed with Covid-19 using the polymerase chain reaction (PCR) method at our hospital. The inclusion criteria encompassed patients who received immune plasma therapy, as well as a control group matched for age, gender, and admission date, who did not undergo immune plasma therapy. Exclusion criteria involved patients with low serum IgA levels, those who did not provide consent for immune plasma therapy, and individuals below the age of 18.

Results: The study comprised a total of 72 patients who received immune plasma therapy and 72 patients in the control group, matched for age and gender, all diagnosed with Covid-19. The median age of the patients was 70 years, ranging from 19 to 91, and 56.9% (41) of them were female. When comparing the immune plasma group with the control group, several significant differences were observed (p<0.05). These included elevated levels of leukocytes, neutrophils, neutrophil-lymphocyte ratio (NLR), glucose, aspartate aminotransferase (AST), sedimentation rate, C-reactive protein (CRP), ferritin, fibrinogen, d-dimer, and low levels of platelets and lymphocytes in the control group. Furthermore, in the immune plasma therapy group, significant associations were found between mortality and lymphocyte count, NLR, AST, CRP, and d-dimer elevation after treatment (p<0.05). Additionally, pre- and post-treatment measurements of troponin, procalcitonin, and ferritin were significantly correlated with mortality (p<0.05).

Conclusion: The administration of immune plasma therapy, involving the transfer of neutralizing antibodies, has demonstrated a favorable impact on laboratory parameters and overall survival in severe cases of Covid-19 pneumonia, particularly during the early stages of the disease.


Download data is not yet available.

Article Details

How to Cite
Bektaş Aksoy, H., Aksoy, İskender, Günaydın, S., Elmas, A., & Dülger, A. C. (2023). Effect of Immune Plasma Therapy on Mortality and Morbidity in Patients with Covid-19: A Retrospective Study. Medical Science and Discovery, 10(7), 472–476. https://doi.org/10.36472/msd.v10i7.989
Research Article
Received 2023-07-08
Accepted 2023-07-17
Published 2023-07-18


Team E. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly. 2020;2(8):113.

Bakanlığı TS. COVID-19 İmmün (Konvalesan) Plazma Tedarik ve Klinik Kullanim Rehberi. Turkey; 2021.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;117(17):9490-6.

Soo Y, Cheng Y, Wong R, Hui D, Lee C, Tsang K, et al. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clinical microbiology and infection. 2004;10(7):676-8.

Lai S. Treatment of severe acute respiratory syndrome. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24(9):583-91.

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24(1):44-6.

Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. Jama. 2020;324(5):460-70.

Horby PW, Landray MJ, Grp RC. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049-59.

Gharbharan A, Jordans CC, Geurtsvankessel C, den Hollander JG, Karim F, Mollema FP, et al. Convalescent plasma for COVID-19. A randomized clinical trial. MEDRxiv. 2020.

Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. The Journal of infectious diseases. 2015;211(1):80-90.

Özel İ. COVID-19 ve konvalesan plazma tedavisi. Atak Yücel A, editör İmmünoloji ve COVID-19.1:67-72.

Özüdoğru O, Güngörmez C, Uyuklu M. Immune plasma therapy in COVID-19 infection: the experience of Siirt.

Eren E, Ulu-Kılıç A, Korkmaz S, Yıldız M, Yüksel RC, Kılınç-Toker A, et al. Retrospective analysis on efficacy of convalescent plasma in acute respiratory distress syndrome due to COVID-19. Sao Paulo Medical Journal. 2021.

Aktimur S, Kayabas A. The impact of convalescent (immune) plasma treatment on the clinical course of covid‐19. Int J Clin Exp Med. 2021;14(2):1226-33.

Most read articles by the same author(s)